Wang Julia Aijun 4

What Happened

• Julia A. Wang, Chief Financial Officer of Labcorp Holdings, received grants on February 10, 2026 comprising 7,100 employee stock options and 2,350 restricted stock units (RSUs). The reported acquisition price is $0.00, indicating these were awards rather than open-market purchases.
• The options were granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan (footnote F1). The filing does not disclose an exercise (strike) price or immediate cash value.

Key Details

• Transaction date: February 10, 2026; Form 4 filed February 12, 2026 (appears timely).
• Grants: 7,100 options (derivative) and 2,350 RSUs; acquisition price shown as $0.00.
• Vesting: Options vest in three equal annual installments beginning on the grant date (F2). RSUs vest in three equal annual installments beginning February 10, 2027 (F4).
• Footnotes: F1 = options granted under 2025 Omnibus Plan; F3–F5 describe RSU mechanics and that the RSU number reflects the aggregate RSUs held by the reporting person.
• Shares owned after the transaction and the options’ strike price are not specified in the provided excerpt.

Context

• These awards are typical executive compensation and do not represent an open-market buy or sell. Options give the right to buy shares in the future; RSUs represent a contingent right to receive shares once vested (and possibly subject to tax withholding).
• The future value of these awards depends on Labcorp’s stock price at vesting/exercise dates; vesting schedules mean the awards are performance/retention-oriented rather than an immediate market commitment.